The Clinical Outcome of FLAG Chemotherapy without Idarubicin in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Reference-Cited by-同舟云学术

The Clinical Outcome of FLAG Chemotherapy without Idarubicin in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Published:2009 Issue:3 Volume:24 Page:498
ISSN:1011-8934
Container-title:Journal of Korean Medical Science
language:en
Short-container-title:J Korean Med Sci

Author:

Lee Se Ryeon¹²,Yang Deok Hwan¹²,Ahn Jae Sook¹²,Kim Yeo Kyeoung¹²,Lee Je Jung¹²,Choi Young Jin³,Shin Ho Jin³,Chung Joo Seop³,Cho Yoon Young⁴,Chae Yee Soo⁴,Kim Jong Gwang⁴,Sohn Sang Kyun⁴,Kim Hyeoung Joon¹²

Affiliation:

1. Blood and Marrow Transplant Center, Hwasun, Korea.

2. Genome Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Hwasun, Korea.

3. Department of Hematology/Oncology, Pusan National University Hospital, Busan, Korea.

4. Department of Oncology/Hematology, KyungPook National University Hospital, Daegu, Korea.

Publisher

Korean Academy of Medical Sciences

Subject

General Medicine

Link

https://synapse.koreamed.org/pdf/10.3346/jkms.2009.24.3.498

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decitabine combined with low-dose cytarabine, aclarubicin and rhG-CSF regimen may be a potential alternative for relapsed/refractory acute myeloid leukemia: A single-center study;memo - Magazine of European Medical Oncology;2023-11-20

2. FLAG based v/s Standard 3 + 7 induction therapy in treatment naïve Acute Myeloid Leukemia: Time to think “beyond anthracyclines”;Leukemia Research;2023-09

3. Effectiveness of chemotherapy using bortezomib combined with homoharringtonine and cytarabine in refractory or relapsed acute myeloid leukemia: a phase II, multicenter, prospective clinical trial;Frontiers in Oncology;2023-08-18

4. Single-Center Retrospective Clinical Evaluation of Venetoclax Combined with HMAs and Half-Dose CAG for Unfit or Refractory/Relapsed AML;OncoTargets and Therapy;2023-06

5. Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia;Cancers;2022-06-06